Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients

dc.contributor.authorFernández Santiago, Rubén
dc.contributor.authorMerkel, Angelika
dc.contributor.authorCastellano, Giancarlo
dc.contributor.authorHeath, Simon
dc.contributor.authorRaya Chamorro, Ángel
dc.contributor.authorTolosa, Eduardo
dc.contributor.authorMartí Domènech, Ma. Josep
dc.contributor.authorConsiglio, Antonella
dc.contributor.authorEzquerra Trabalón, Mario
dc.date.accessioned2020-10-27T10:53:08Z
dc.date.available2020-10-27T10:53:08Z
dc.date.issued2019-07-23
dc.date.updated2020-10-27T10:53:08Z
dc.description.abstractBackground: Parkinson's disease (PD) is characterized by the loss of midbrain dopaminergic neurons (DAn). Previously, we described the presence of DNA hyper- and hypo-methylation alterations in induced pluripotent stem cells (iPSC)-derived DAn from PD patients using the Illumina 450K array which prominently covers gene regulatory regions. Methods: To expand and contextualize previous findings, we performed the first whole-genome DNA bisulfite sequencing (WGBS) using iPSC-derived DAn from representative PD subjects: one sporadic PD (sPD) patient, one monogenic LRRK2-associated PD patient (L2PD), and one control. Results: At the whole-genome level, we detected global DNA hyper-methylation in the PD which was similarly spread across the genome in both sPD and L2PD and mostly affected intergenic regions. Conclusion: This study implements previous epigenetic knowledge in PD at a whole genome level providing the first comprehensive and unbiased CpG DNA methylation data using iPSC-derived DAn from PD patients. Our results indicate that DAn from monogenic or sporadic PD exhibit global DNA hyper-methylation changes. Findings from this exploratory study are to be validated in further studies analyzing other PD cell models and patient tissues.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec697533
dc.identifier.issn1868-7075
dc.identifier.pmid31337434
dc.identifier.urihttps://hdl.handle.net/2445/171541
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s13148-019-0701-6
dc.relation.ispartofClinical Epigenetics, 2019, vol. 11
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/311736/EU//PD-HUMMODEL
dc.relation.urihttps://doi.org/10.1186/s13148-019-0701-6
dc.rightscc-by (c) Fernández Santiago, Rubén et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationMalaltia de Parkinson
dc.subject.classificationADN
dc.subject.classificationMetilació
dc.subject.otherParkinson's disease
dc.subject.otherDNA
dc.subject.otherMethylation
dc.titleWhole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
697533.pdf
Mida:
739.03 KB
Format:
Adobe Portable Document Format